Perrotta Francesco, Perrini Marco Paolo
Department of Anesthesia and Intensive Care Unit, IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini, 1, 71013 San Giovanni Rotondo, FG, Italy.
Department of Anesthesia and Intensive Care Unit, Università degli Studi di Foggia, Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia, 1, 71122 Viale Pinto, FG, Italy.
Medicina (Kaunas). 2021 Apr 28;57(5):424. doi: 10.3390/medicina57050424.
Carbapenem-resistant (CRE) are a serious public health threat. Infections due to these organisms are associated with significant morbidity and mortality. Among them, metallo-β-lactamases (MBLs)-producing are of global concern today. The ceftazidime/avibactam combination and the ceftazidime/avibactam + aztreonam combination currently represent the most promising antibiotic strategies to stave off these kinds of infections. We describe the case of a patient affected by thrombotic thrombocytopenic purpura (TTP) admitted in our ICU after developing a hospital-acquired SarsCoV2 interstitial pneumonia during his stay in the hematology department. His medical conditions during his ICU stay were further complicated by a NDM sepsis. To our knowledge, the patient had no risk factors for multidrug-resistant bacteria exposure or contamination during his stay in the hematology department. During his stay in the ICU, we treated the sepsis with a combination therapy of ceftazidime/avibactam + aztreonam. The therapy solved his septic state, allowing for a progressive improvement in his general condition. Moreover, we noticed that the negativization of the hemocultures was also associated to a decontamination of his known rectal colonization. The ceftazidime/avibactam + aztreonam treatment could not only be a valid therapeutic option for these kinds of infections, but it could also be considered as a useful tool in selected patients' intestinal decolonizations.
耐碳青霉烯类肠杆菌科细菌(CRE)是严重的公共卫生威胁。这些病原体引起的感染与显著的发病率和死亡率相关。其中,产金属β-内酰胺酶(MBL)的细菌目前受到全球关注。头孢他啶/阿维巴坦联合用药以及头孢他啶/阿维巴坦+氨曲南联合用药目前是抵御这类感染最有前景的抗生素策略。我们描述了一例血栓性血小板减少性紫癜(TTP)患者的病例,该患者在血液科住院期间发生医院获得性新型冠状病毒2型间质性肺炎后入住我们的重症监护病房(ICU)。他在ICU住院期间的病情因新德里金属β-内酰胺酶(NDM)败血症而进一步复杂化。据我们所知,该患者在血液科住院期间没有接触或感染多重耐药菌的风险因素。在他入住ICU期间,我们用头孢他啶/阿维巴坦+氨曲南联合疗法治疗败血症。该疗法解决了他的败血症状态,使他的总体状况逐渐改善。此外,我们注意到血培养转阴也与他已知的直肠定植菌清除有关。头孢他啶/阿维巴坦+氨曲南治疗不仅可能是这类感染的有效治疗选择,而且在选定患者的肠道去定植方面也可被视为一种有用的工具。